Her advice
There is a dearth of literature specifically tackling the prevalence of DED before and during GLP-1 therapy, so in the absence of definitive prospective, randomized clinical trials, both eye care providers and GLP-1 prescribers should be aware of potential DED complications and how to ensure patients can experience all the benefits of these groundbreaking drugs without compromising ocular health
Endocr Rev 16:390410 Feinle C, Chapman IM, Wishart J, Horowitz M (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men
Common Protocols & Dosage IV glutathione therapy is customized based on the patients condition
3D), characterized by increased proximity to Stranger 1 and reduced non-social exploration
Living with Long COVID, ME/CFS, dysautonomia, or MCAS is a profoundly challenging experience that often requires navigating a medical system ill-equipped to handle complex, multi-systemic illnesses